Welcome to our dedicated page for Prime Medicine SEC filings (Ticker: PRME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Prime Medicine’s latest 10-K can feel like decoding advanced genetics—hundreds of pages on Prime Editing science, clinical-trial risk, and cash runway. If you’ve ever searched for “Prime Medicine SEC filings explained simply” or wondered how to spot pivotal 8-K trial disclosures before the market reacts, this page solves that problem. Stock Titan’s AI scans each document the moment it hits EDGAR, flagging what matters to biotech investors—pipeline milestones, collaboration revenue, and dilution warnings.
Use our platform to jump directly to the numbers and narratives that drive valuation. Need the “Prime Medicine quarterly earnings report 10-Q filing” to track R&D spend? Curious about “Prime Medicine insider trading Form 4 transactions” after fresh data releases? Our real-time engine delivers plain-language synopses, side-by-side charts, and instant alerts. We also translate dense proxy language—think “Prime Medicine proxy statement executive compensation”—into clear tables and context.
- “Prime Medicine annual report 10-K simplified” with AI-generated section summaries
- “Prime Medicine earnings report filing analysis” highlighting cash burn and runway
- “Prime Medicine Form 4 insider transactions real-time” for scientist and CEO trades
- “Prime Medicine 8-K material events explained” within minutes of publication
- “Understanding Prime Medicine SEC documents with AI” through interactive cues
- “Prime Medicine executive stock transactions Form 4” for pattern spotting
Whether you follow gene-editing breakthroughs or monitor dilution risk, our comprehensive coverage and AI-powered summaries turn complex filings into actionable insight—saving hours and improving decision quality.
Prime Medicine (PRME) – Form 4 insider transaction filed 08/01/2025. ARCH Venture entities, collectively 10% owners, disclosed a purchase of 3,030,300 common shares at $3.30 per share (approx. $10.0 million). The buyer of record is ARCH Venture Fund XII, L.P.
Post-transaction indirect holdings stand at:
- ARCH Venture Fund X, L.P.: 6,128,297 shares (unchanged)
- ARCH Venture Fund X Overage, L.P.: 6,128,297 shares (unchanged)
- ARCH Venture Fund XII, L.P.: 6,230,300 shares (up from zero disclosed in this filing)
Total indirect ownership across the reporting group rises to roughly 18.5 million shares. The filing is one of two joint reports; Robert Nelsen is filing separately for his direct holdings.
Key take-away: A sizable open-market purchase by a long-term venture backer at a depressed price signals increased confidence in PRME’s prospects and tightens insider alignment with public shareholders.
Prime Medicine, Inc. (PRME) – Form 4 insider transaction
Director and 10% owner David R. Liu disclosed the purchase of 21,000 shares of Prime Medicine common stock on 23-Jun-2025. The trade was executed under a previously adopted Rule 10b5-1 plan dated 3-Mar-2025, indicating it was pre-scheduled rather than opportunistic.
The weighted-average purchase price was $2.162 per share, with individual trades occurring between $2.06 – $2.25. Following the transaction, Liu’s direct ownership increased to 20,219,945 shares, an incremental addition of roughly 0.10 % to his existing stake.
No derivative securities were reported, and no sales occurred. While the absolute dollar value of the purchase (~$45,400) is modest relative to Liu’s overall holding, insider buying—especially by a high-ownership director—can be interpreted as a vote of confidence in the company’s prospects at current price levels.
FAQ
What is the current stock price of Prime Medicine (PRME)?
What is the market cap of Prime Medicine (PRME)?
